Skip to main content
Retour
ANRO logo

Alto Neuroscience, Inc.

Qualité des données : 100%
ANRO
NYSE Healthcare Biotechnology
20,19 €
▲ 0,17 € (0,85%)
Cap. Boursière : 627,23M
Fourchette du Jour
19,41 € 20,46 €
Fourchette 52 Semaines
1,60 € 25,17 €
Volume
140 803
Moyenne 50J / 200J
18,43 € / 10,24 €
Clôture Précédente
20,02 €

Quick Summary

Historique des Prix

Tendances Financières

Comparaison Sectorielle

vs médiane du secteur Healthcare (627 pairs)

Métrique Action Médiane du Secteur
P/E -9,9 0,3
P/B 4,2 3,0
ROE % -41,8 3,7
Net Margin % 3,8
Rev Growth 5Y % 10,0
D/E 0,0 0,2

Objectif de Cours des Analystes

Hold
26,33 € +30.4%
Low: 16,00 € High: 35,00 €
BPA Prévisionnel
-2,41 €
CA Est.
0,0

Estimations de Bénéfices

Période BPA Est. CA Est. Analystes
FY2030 1,09 €
1,09 € – 1,09 €
294,45M 2
FY2029 -2,41 €
-2,41 € – -2,41 €
49,02M 4
FY2028 -2,88 €
-4,11 € – -2,15 €
9,30M 6

Dividend History

Yield

0,00%

Payout Ratio

N/A

Growth (3Y)

N/A

Growth (5Y)

N/A

No dividend history available.

Points Clés

Debt/Equity of 0,03 — conservative balance sheet
Negative free cash flow of -51,79M
PEG of 0,65 suggests growth is underpriced

Croissance

Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Qualité

Return on Equity
-41,80%
ROIC-32,00%
Net MarginN/A
Op. MarginN/A

Sécurité

Debt / Equity
0,03
Current Ratio15,69
Interest Coverage-26,88

Valorisation

P/E Ratio
-9,92
Forward P/EN/A
P/B Ratio4,15
EV/EBITDAN/A
Dividend Yield0,00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) N/A Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 0,0 Net Income (TTM) -63,24M
ROE -41,80% ROA -34,24%
Gross Margin N/A Operating Margin N/A
Net Margin N/A Free Cash Flow (TTM) -51,79M
ROIC -32,00% FCF Growth (3Y) N/A
Safety
Debt / Equity 0,03 Current Ratio 15,69
Interest Coverage -26,88
Dividends
Dividend Yield 0,00% Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -9,92 Forward P/E N/A
P/B Ratio 4,15 P/S Ratio N/A
PEG Ratio 0,65 Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -8,26%
Market Cap 627,23M Enterprise Value 455,15M

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 0,0 0,0 0,0 0,0 210 000,0
Net Income -63,24M -61,43M -36,31M -27,71M -9,19M
EPS (Diluted) -2,19 -2,50 -1,35 -1,08 -0,36
Gross Profit -661 000,0 -502 000,0 0,0 -342 000,0 65 000,0
Operating Income -66,36M -68,61M -37,81M -29,19M -12,06M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 184,69M 177,54M 86,63M 50,85M 28,79M
Total Liabilities 33,55M 26,08M 158,30M 89,26M 41,27M
Shareholders' Equity 151,14M 151,46M -71,67M -38,41M -12,48M
Total Debt 4,41M 16,94M 9,99M 82,11M 38,16M
Cash & Equivalents 176,48M 168,23M 82,55M 48,34M 25,71M
Current Assets 177,72M 169,34M 85,39M 49,22M 27,68M
Current Liabilities 11,33M 10,01M 5,61M 5,56M 1,81M